STOCKHOLM, Dec. 28, 2020 /PRNewswire/ -- C-RAD announces
today that C-RAD has been selected as the partner to implement
surface tracking technology for three proton cancer treatment
centers in the US.
C-RAD offers a specific version of its Catalyst™ System for use
in proton and particle therapy - Catalyst PT. It is based on the
patented Catalyst technology and software as well as the hardware
are tailored for the application in this environment.
The Catalyst system is delivered with the complete software
suite with modules for Respiratory Gating, Patient Setup and
Positioning and Motion Monitoring. The C-RAD SIGRT solution
provides a continuous monitoring of the patient during a treatment
fraction. The system is delivered with interfaces that allow to
interrupt the treatment beam if patient motion is above a
clinically defined threshold.
C-RAD Sentinel 4DCT™ is an easy-to-use, laser-based optical
surface scanning system with functionality for four-dimensional CT
image reconstruction and gated imaging in a CT room.
"There is a trend within radiation therapy towards high
precision treatments. The goal is to improve treatment success and
at the same time spare the healthy tissue to minimize side
effects." continues Tim Thurn, "To
the benefit of the patient, there is a strong motivation to reduce
the time for patient setup and positioning. The C-RAD solution is
made to support such treatments in a safer and more efficient
The total order has a value of 15 MSEK for C-RAD. Delivery and
installation for the first center are expected to be concluded
during the next three months. The other sites will follow in 2021
C-RAD develops surface-guided imaging solutions for radiation
therapy to allow highly accurate dose delivery to the tumor, and at
the same time, to protect healthy tissue from unwanted exposure.
Using high-speed 3D cameras combined with augmented reality, C-RAD
supports the initial patient setup process and monitors the
patient's motion during treatment to ensure high confidence, an
efficient workflow, and improved accuracy. C-RAD monitors the
patient's motion without the use of tattoos or additional imaging
dose, to deliver the highest level of patient safety and
C-RAD. Inspiring excellence in cancer treatment.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit
For further information:
Tim Thurn, CEO C-RAD AB, Phone
+46-18-666930, Email email@example.com
This information is information that C-RAD AB (publ) is obliged
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication at 15:15 CET on December
This information was brought to you by Cision
The following files are available for download: